Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy

Journal of Medicinal Chemistry

Volumn 41, Issue 19, 1998, Pages 3572-3581

  Florent, Jean Claude ^a   Dong, Xia ^a   Gaudel, Gilbert ^a   Mitaku, Sofia ^a   Monneret, Claude ^a   Gesson, Jean Pierre ^b   Jacquesy, Jean Claude ^b   Mondon, Martine ^b   Renoux, Brigitte ^b   Andrianomenjanahary, Solo ^c   Michel, Sylvie ^c   Koch, Michel ^c   Tillequin, François ^c   Gerken, Manfred ^d   Czech, Joerg ^d   Straub, Rainer ^d   Bosslet, Klaus ^d  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c Laboratoire de Pharmacognosie   (France)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA GLUCURONIDASE; CARBAMIC ACID DERIVATIVE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DAUNORUBICIN; DOXORUBICIN; HUMAN MONOCLONAL ANTIBODY; N [2 O (BETA DEXTRO GLUCOPYRANOSIDEURONIC ACID) 5 FLUOROBENZYLOXYCARBONYL] DOXORUBICIN; N [2 O (BETA DEXTRO GLUCOPYRANOSIDEURONIC ACID) 5 NITROBENZYLOXYCARBONYL] DOXORUBICIN; N [2 O (GLUCOPYRANOSIDEURONIC ACID) 5 CHLOROBENZYLOXYCARBONYL] DOXORUBICIN; N [4 O (BETA DEXTRO GLUCOPYRANOSIDE) URONIC ACID) 3 FLUOROBENZYLOXYCARBONYL] DOXORUBICIN; N [4 O (BETA DEXTRO GLUCOPYRANOSIDEURONIC ACID) 3 CHLOROBENZYLOXYCARBONYL] DOXORUBICIN; N [4 O (METHYL BETA DEXTRO GLUCOPYRANOSYLURONATE) 3 NITROBENZYLOXYCARBONYL] DOXORUBICIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME SUBSTRATE; LEUKEMIA CELL LINE; MOUSE; NONHUMAN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; DAUNORUBICIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ESCHERICHIA COLI; GLUCURONATES; GLUCURONIDASE; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; LEUKEMIA L1210; MICE; PRODRUGS; RATS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 15144361344     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970589l     Document Type: Article

References (41)

1. Connors, T. A. Antitumor Drug with Latent Activity. Biochemie 1978, 60, 979-987.
2. (a) Bagshawe, K. D. Antibody Directed Enzymes Revive Anti-cancer Prodrugs Concept. Br. J. Cancer 1987, 56, 531-532.
3. (b) Bagshawe, K. D.; Springer, C. J.; Searle, F.; Antoniw, P.; Sharma, S. K.; Melton, R. G.; Sherwood, R. F. A Cytotoxic Agent Can Be Generated Selectively at Cancer Sites. Br. J. Cancer 1988, 58, 700-703.
4. (a) Senter, P. D.; Saulnier, M. G.; Schreiber, G. J.; Hirschberg, D. L.; Brown, J. P.; Hellstrom, I.; Hellstrom, K. E. Antitumor Effect of Antibody-Alkaline Phosphatase Conjugates in Combination with Etoposide Phosphate. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4842-4846.
5. (b) Haisma, J. J.; Boven, E.; van Muijen, M.; De Vries, K.; Pinedo, H. M. Analysis of a Conjugate between Anti-carcinoembryonic Antigen Monoclonal Antibody and Alkaline Phosphatase for Specific Activation of the Prodrug Etoposide Phosphate. Cancer Immunol. Immunother. 1992, 32, 343-348.
6. Wallace, P. M.; Senter, P. D. Selective Activation of Anticancer Prodrugs by Monoclonal Antibody-Enzyme Conjugates. Methods Find. Exp. Clin. Pharmacol. 1994, 16, 505-512.
7. Huennekens, F. M. Tumor Targeting: Activation of Prodrugs by Enzyme-Monoclonal Conjugates. Tibtech 1994, 12, 234-239.
8. Jungheim, L. N.; Shepherd, T. A. Design of Antitumor, Prodrugs: Substrates for Antibody-Targeted Enzymes. Chem. Rev. 1994, 94, 1553-1566.
9. Deonarain, M. P.; Epenetos, A. A. Targeting Enzymes for Cancer Therapy: Old Enzymes in New Roles. Br. J. Cancer 1994, 70, 786-794.
10. Bagshawe, K. D. Antibody-directed Enzyme Prodrug Therapy (ADEPT). J. Controlled Rel. 1994, 28, 187-193.
11. Bagshawe, K. D. Antibody-directed Enzyme Prodrug Therapy: A Review. Drug Dev. Res. 1995, 34, 220-230.
12. Springer, C. J.; Niculescu-Duvaz I. Antibody-Directed Enzyme Prodrug Therapy (ADEPT) with Mustard Prodrugs. Anti-Cancer Drug Des. 1995, 10, 361-372.
13. Niculescu-Duvaz, I.; Springer, C. J. Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy. Curr. Med. Chem. 1995, 2, 687-706.
14. Blakey, D. C.; Burke, P. J.; Davies, D. H.; Dowell, R. I.; Melton, R. G.; Springer, C. J.; Wright, A. F. Antibody-directed Enzyme Prodrug Therapy (ADEPT) for treatment of major solid disease. Biochem. Soc. Trans. 1995, 23, 1047-1050.
15. Melton, R. G.; Sherwood, R. F. Antibody-Enzyme Conjugates for Cancer Therapy. J. Natl. Cancer Inst. 1996, 88, 153-165.
16. Melton, R. G.; Knox, R. J.; Connors, T. A. Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Drugs Future 1996, 21, 167-181.
17. Hay, M. P.; Denny, W. A. Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Drugs Future 1996, 21, 917-931.
18. Niculescu-Duvaz, I.; Springer, C. J. Antibody-Directed Enzyme Prodrug Therapy (ADEPT): a Review. Adv. Drug Delivery Rev. 1997, 26, 151-172.
19. Senter, P. D.; Svensson, H. P. A Summary of Monoclonal Antibody-Enzyme/Prodrug. Adv. Drug Delivery Rev. 1996, 22, 341-350.
20. Sherwood, R. F. Advanced Drug Delivery Reviews: Enzyme Prodrug Therapy. Adv. Drug Delivery Rev. 1996, 22, 269-288.
21. Springer, C. J.; Marais, R. Preparation of ras Inhibitor Prodrugs Useful In Treating Tumors. Improvements Relating To Prodrugs. PCT International Application WO 95/03,830, 1995; Chem. Abstr. 1995, 123, 56563m.
22. Arcamone, F. Doxorubicin Antibiotics. Medicinal Chemistry; Academic Press: New York, 1981; Vol. 17.
23. Gerken, M.; Bosslet, K.; Seeman, G.; Hoffmann, D.; Sedlacek, H.-H. Anthracyclin-glycosyl-Prodrugs, Verfahren zu ihrer Herstellung und ihre Verwendung in Kombination mit funktionalisierten tumorspezifischen Enzymconjugaten. Eur. Patent EP 0441 218 A2, 1991.
24. Haisma, H. J.; Boven, E.; van Muijen, M.; de Jong, J.; van der Vijgh, W. J. F.; Pinedo, H. M. A Monoclonal Antibody-β-glucuronidase Conjugate as activator of the Prodrug Epirubicin-Glucuronide for Specific Treatment of Cancer. Br. J. Cancer 1992, 66, 474-478.
25. Haisma, H. J.; van Muijen, M.; Pinedo, H. M.; Boven, E. Comparison of Two Anthracycline-Based Prodrugs for Activation by a Monoclonal Antibody-β-glucuronisase Conjugate in the Specitif Treatment of Cancer. Cell Biophys. 1994, 24-25, 185-192.
26. Andrianomenjanahary, S.; Dong, X.; Florent, J.-C.; Gaudel, G.; Gesson, J.-P.; Jacquesy, J.-C.; Koch, M.; Michel, S.; Mondon, M.; Petit, P.; Renoux, B.; Tillequin, F. Synthesis of Novel Targeted Pro-Prodrugs of Anthracyclines Potentially Activated by a Monoclonal Antibody Galactosidase Conjugate. Bioorg. Med. Chem. Lett. 1992, 9, 1093-1096.
27. Gesson, J. P.; Jacquesy, J.-C.; Mondon, M.; Petit, P.; Renoux, B.; Andrianomenjanahary, S.; Dufat-Trinh Van, H.; Koch, M.; Michel, S.; Tillequin, F.; Florent, J.-C.; Monneret, C.; Bosslet, K.; Czech, J.; Hoffmann, D. Prodrugs of Anthracyclines for Chemotherapy Via Enzyme-Monoclonal Antibody Conjugates. Anti-Cancer Drug Des. 1994, 9, 409-423.
28. Azoulay, M.; Florent, J.-C.; Monneret, C.; Gesson, J. P.; Jacquesy, J.-C.; Tillequin, F.; Koch, M.; Czech, J.; Hoffman, D. Prodrugs of Anthracycline Antibiotics Suited for Tumor-Specific Activation. Anti-Cancer Drug Des. 1995, 10, 441-450.
29. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A Novel Linkage Applicable in Prodrug Design. J. Med. Chem. 1981, 24, 479-480.
30. Bosslet, K.; Czech, J.; Lorenz, P.; Sedlacek, H. H.; Schuermann, M.; Seemann, G. Molecular and Functional Characterization of a Fusion Protein Suited for Tumor Specific Prodrug Activation. Br. J. Cancer 1992, 65, 234-238.
31. Stahl, P. D.; Fishman, W. H. In Methods of Enzymatic Analysis, 3rd ed.; Bergmeyer, H. U., Ed.; Verlag Chemie: Weinheim, 1984; Vol. 4, pp 246-256.
32. Bukhari, M. A.; Everett J. L.; Ross, W. C. J. Aryl-2-haloalkylamines. XXVI. Glucuronic, Sulfuric and Phosphoric Esters of p-Bis-(2-chloroethyl)aminophenol. Biochem. Pharmacol. 1972, 21, 963-967.
33. Bollenback, G. N.; Long, J. W.; Benjamin, D. G.; Lindquist, J. A. The Synthesis of Aryl-D-Glucopyranosiduronic Acids. J. Am. Chem. Soc. 1955, 77, 3310-3315.
34. Gingras M.; Chan, T. H. Silver-Assisted Reactions of Organotin Oxides. A Mild, Neutral and Anhydrous One-Step Conversion of Primary Organic Halides to Alcohols. Tetrahedron Lett. 1989, 30, 279-282.
35. Bosslet, K.; Czech, J.; Hoffman, D. Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis. Cancer Res. 1994, 54, 2151-2159.
36. Bosslet, K.; Czech, J.; Seemann, G.; Monneret, C.; Hoffmann, D. Cell Biophys. 1994, 24-25, 51-63.
37. Bosslet, K. Unpublished results.
38. Bosslet, K.; Czech, J.; Hoffmann, D. A Novel One-Step Tumor-Selective Prodrug Activation System. Tumor Targeting 1995, 1, 45-50.
39. Bosslet, K.; Straub, R.; Gerken, M.; Petrul, H.; Czech, J.; Florent, J.-C.; Koch, M.; Tillequin, F.; Schmidt, C.; Monneret, C.; Gesson, J.-P. Neue Ansätze zur spezifischen Antitumor-Behandlung: ADEPT, FMPA und PMT. In Neue therapeutische Prinzipien in der Krebsbehandlung; Staab, H. J., Drings, P., Eds.; Georg Thieme Verlag: Stuttgart, 1996; pp 123-130.
40. Weissman, G.; Zurier, R. B.; Spieler, P. Z. Mechanisms of lysosomal enzyme release from Leukocytes Exposed to Immune Complexes and other Particles. J. Exp. Med. 1971, 134, 521-536.
41. Boyer, M. J.; Tannock, I. F. Lysosomes, Lysosomal Enzymes, and Cancer. Adv. Cancer Res. 1993, 53, 269-291.